Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor.

Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

Abstract: An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor.

Abstract: An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.

Abstract: An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.

Abstract: A method of treating neurodegenerative disorders of the brain and spinal cord is disclosed. The therapeutic agent is a polyethylene glycol linked protein.

Abstract: A method of treating neurodegenerative disorders of the brain and spinal cord using a novel ethropoietic agent.

Abstract: The invention provides an expression vector useful in expressing foreign genes in procaryotes. The vector consists of the promotor/operator region and initiation point of translation of the mg1 operon. This combination is referred to as a regulation sequence. In order to prepare this, desired portions of the mg1 operon are cut from the genome of a cell which can utilize galactose via appropriate restriction endonucleases. This is then inserted into a DNA vector.

Abstract: The invention concerns a cholesterol oxidase, a process for the production of a recombinant cholesterol oxidase, a DNA sequence suitable for this process which causes a cytoplasmatic expression of the recombinant cholesterol oxidase in a host bacterium as well as the recombinant cholesterol oxidase obtianed in this way.

Abstract: The recombinant DNA according to the present invention contains a regulator region which is different from the pfl gene; a promoter region upstream from the gene which contains a -35/-10 promoter sequence; a regulator region upstream from the promoter region which contains a sequence (I) 5'-GAGATATGATCTATATCAATTTC-3' or a 23 base pair sequence which is at least 80% identical to positions 6-10 and 15-19 of said sequence (I) but not having C at position 8 and/or G at position 17. An expression vector according to the present invention contains a recombinant DNA according to the present invention ligated into a suitable vector molecule and methods are also described for expression the DNA.

Abstract: In a process for the production of recombinant, biologically active, eukaryotic alkaline phosphatase a DNA sequence coding for a eukaryotic alkaline phosphatase is expressed in a prokaryotic host cell and the expression product is obtained in an active form by cell lysis, solubilization under denaturing conditions and subsequent renaturation. In this process the renaturation step is carried out in the presence of one or several stabilizing agents.

Abstract: The invention concerns a glucose-6-phosphate dehydrogenase which contains the amino acid sequence shown in SEQ ID NO:1 as well as a DNA coding for it and a process for the isolation of an enzyme according to the present invention.

Abstract: The invention concerns a glucose-6-phosphate dehydrogenase which contains the amino acid sequence shown in SEQ ID NO:1 as well as a DNA coding for it and a process for the isolation of an enzyme according to the present invention.

Abstract: The new type II restriction endonuclease Ssp4800I has the following recognition sequence: ##STR1## and preferably cleaves at the cleavage site defined by the arrows. It is preferably obtainable from microorganisms of the genus Streptomyces.